February 7, 2017
Allergan hears NASEM’s call for fighting preventable blindness in USA
Allergan said on Tuesday it wants to commit to working on preventable blindness in the USA.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
February 6, 2017
Health Risks of Smoking and Ways to Quit
Quitting smoking improves health in smokers of all ages, National Institute of Health (NIH) claims in its article about methods…
February 6, 2017
Advanced Oncotherapy exits deal with Sinophi for its China&SE Asia proton therapy system
Advanced Oncotherapy has dropped taking legal measures against Sinophi Healthcare Limited (Sinophi), as the companies have agreed to terminate the purchase from March and October 2015.
February 6, 2017
Kiadis Pharma in phase 3 with leukemia drug ATIR101
Kiadis Pharma has started its phase III trial with its major products for blood cancer hematopoietic stem cell transplantation (HSCT) ATIR101.
February 6, 2017
Innate Pharma’s acute myeloid leukemia drug testing disappoints
Innate Pharma’s “EffiKIR” trial of lirilumab as a single agent maintenance treatment in elderly patients with acute myeloid leukemia (AML) in first complete remission, did not meet its primary efficacy endpoint of leukemia-free survival (LFS).
February 6, 2017
Ablynx submits its thrombosis antibody to EMA
Ablynx has applied its caplacizumab to European Medicines Agency for approval to use it for a form of blod clotting disorder.
February 6, 2017
TiGenix to present results of Crohn`s disease drug trial at ECCO
TiGenix will present results from its Phase III trial of Crohn`s disease drug, named Cx601, at the upcoming 12th Annual Congress of the…
February 6, 2017
Portola nets $150M deal with HealthCare Royalty Partners
Portola Pharmaceuticals has signed a $150 million royalty deal with HealthCare Royalty Partners (HCR).
February 4, 2017
World Cancer Day: Worldwide cases of cancer predicted to reach 21.7 million by 2030
Coordinated by Union for International Cancer Control (UICC), World Cancer Day is this year taking place under the tagline ‘We can. I can.’ and explores how everyone – as a collective or as individuals – can do their part to reduce the global burden of cancer.
February 3, 2017
Sobi negotiates sale of its Partner Products business area
Swedish Orphan Biovitrum is negotiating with a private equity firm regarding a possible sale of its Partner Products business area excluding Kineret and Orfadin.